The national government plans for today the arrival of a new shipment of 1,114,000 doses of Sinopharm vaccines, from China, to advance with the Federal Immunization Plan against covid-19.
This batch will allow the initiation of vaccination schedules among children from three to 11 years old, as announced last Friday by the Ministers of Health, Carla Vizzotti, and Education, Jaime Perzyck, at a press conference at the Casa Rosada.
With this shipment, the laboratory of Chinese origin will have completed its first contract with Argentina.
Last week, the national government had announced that the National Administration of Drugs, Food and Medical Technology (Anmat) had given its authorization for the use of Sinopharm in children between three and 11 years old, with the aim of incorporating that age group into the inoculation plan before the end of the year.
The immunization of these children would represent “an individual benefit of collective impact, due to its relevance to sustain full attendance” in schools across the country, Vizzotti had said.
“Argentina ends 2021 with its entire population over three years covered and protected. We have the stock to start this vaccination and complete the schedules,” the head of the national health portfolio had highlighted.
In addition, Vizzotti had expressed that a call for the Federal Health Council was scheduled for today to evaluate how they follow the steps for the vaccination of children and young people against the coronavirus, either in schools or in immunization centers.
In Tucumán, the vaccination plan is advancing with 15-year-old adolescents, who are receiving – like 16 and 17 – vaccines from Moderna and Pfizer.
Since the beginning of the campaign, Argentina has received 70,861,425 vaccines, which entered the country since the beginning of the pandemic.
Of the total received so far, 28,856,000 correspond to Sinopharm, 14,183,210 belong to Sputnik V (10,125,655 from component 1, and 4,057,555 from component 2), and 3,129,125 to Sputnik V produced in Argentina by the Richmond Laboratory (1,179,625 for the first component, and 1,949,500 for the second).
20,011,600 doses correspond to the AstraZeneca firm (580,000 Covishield; 1,944,000 received by the Covax mechanism, 15,695,400 from AstraZeneca and Oxford whose active ingredient was produced in Argentina; 1,242,400 donated by Spain and 549,600 by Canada). Meanwhile, 3,500,000 correspond to doses of Moderna donated by the United States, 600,000 to CanSino and 581,490 to Pfizer.